Loading... Please wait...
Sort by:

 

firstview-jpg.jpgFirstView reports deliver unique insight into current and future pharma market dynamics through quantitative surveys with physicians. With the ability to query a 1-million strong online physician community worldwide, FirstView provides essential data to support effective decision making in major disease areas and on key industry issues.

  • Market Access Impact: Growth Hormone Deficiency (US)
    Learn More Market Access Impact: Growth Hormone Deficiency (US)
    GHD: Has one brand found the winning market access strategy in the US? Market barriers affect nearly 40% of growth hormone prescriptions in the US, and most brands lose market share because of them. But one brand has...
  • Market Access Impact: Growth Hormone Deficiency (EU5)
    Learn More Market Access Impact: Growth Hormone Deficiency (EU5)
    GHD: Has one brand found the winning market access strategy in Europe? Market barriers affect nearly 25% of growth hormone prescriptions in Europe, costing most brands market share. But one brand’s efforts to...
  • Medical Affairs Reputations: HIV (US)
    Learn More Medical Affairs Reputations: HIV (US)
    HIV: Hard work is paying off for the top 2 medical affairs teams in the US. How is your team doing? In the past 6 months, the medical affairs teams for two leading HIV treatments reached more doctors than any other...
  • Medical Affairs Reputations: HIV (EU5)
    Learn More Medical Affairs Reputations: HIV (EU5)
    HIV: Hard work is paying off for the top 2 medical affairs teams in Europe. How is your team doing? In the past 6 months, the medical affairs teams for two leading HIV treatments reached up to 91% of the doctors we...
  • Market Access Impact: Renal Cell Carcinoma (EU5)
    Learn More Market Access Impact: Renal Cell Carcinoma (EU5)
    Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them? We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when...
  • Market Access Impact: Renal Cell Carcinoma (US)
    Learn More Market Access Impact: Renal Cell Carcinoma (US)
    Market barriers boost net share for 6 major RCC treatments in US. Is your brand one of them? We researched 9 renal cell carcinoma (RCC) treatments to see what happens to their share of the US market when oncologists...
  • Market Access Impact: HIV (US)
    Learn More Market Access Impact: HIV (US)
    Can prescription barriers help other HIV brands catch up to the runaway market leader? In the US HIV treatment market, the #1 brand has a 10% market share lead over its nearest rival. Will market barriers be the...
  • Market Access Impact: HIV (EU5)
    Learn More Market Access Impact: HIV (EU5)
    Can prescription barriers help the 2nd and 3rd place HIV brands catch up to the runaway market leader? In the European HIV treatment market, the leading brand is comfortably ahead—but can market barriers help...
  • Market Access Impact: Psoriasis (EU5)
    Learn More Market Access Impact: Psoriasis (EU5)
    Price and reimbursement are stopping physicians from prescribing the drugs they want.  In the psoriasis market, brands are gaining or losing market share due to, in many cases, avoidable barriers. There's a clear...
  • Market Access Impact: Psoriasis (US)
    Learn More Market Access Impact: Psoriasis (US)
    See how formularies, reimbursement, and price are ensuring the disparity in market share among brands In the psoriasis market, brands are gaining or losing market share to the competition due to the effects of market...
  • Medical Affairs Reputations: Renal Cell Carcinoma (US)
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (US)
    Opdivo’s medical affairs team working overtime to engage oncologists. Is it paying off? Opdivo’s medical affairs team has been busy. Since late 2015, when the Anti-PD-1 monoclonal antibody got FDA approval...
  • Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
    4 medical affairs teams working hard to engage oncologists. Which one gets top marks?  European medical affairs teams for four renal cell carcinoma (RCC) treatments have been working overtime, interacting with...
  • Medical Affairs Reputations Non-small Cell Lung Cancer (EU5)
    Learn More Medical Affairs Reputations Non-small Cell Lung Cancer (EU5)
    Four medical affairs teams battling it out for top spot. How does your team compare? In the fiercely competitive European non-small cell lung cancer (NSCLC) treatment market, one medical affairs team leads. But for how...
  • Medical Affairs Reputations Non-small Cell Lung Cancer (US)
    Learn More Medical Affairs Reputations Non-small Cell Lung Cancer (US)
    Top medical affairs team safely ahead, but competition for 2nd and 3rd place is fierce In the US non-small cell lung cancer (NSCLC) treatment market, competition among medical affairs teams is fierce. The top team may...
  • Medical Affairs Reputations: Psoriasis (US)
    Learn More Medical Affairs Reputations: Psoriasis (US)
    One brand’s medical affairs team scores 30% higher than any other. Can your team catch up? Ranked for overall quality of interactions, the leading medical affairs team in the US psoriasis treatment market beats...
  • Market Access Impact: Melanoma (EU5)
    Learn More Market Access Impact: Melanoma (EU5)
    Compare 7 leading melanoma drugs. See why the 2nd-place brand is closing in on the top player When oncologists can’t prescribe the drugs they want, brands lose market share—share that goes to the competition...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved